Navigation Links
Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
Date:8/13/2009

usiness is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this Quarterly Report on Form 10-Q to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended June 30, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... 2014 Nashville Fertility Center announced that ... for the American Society for Reproductive Medicine (ASRM), a ... in reproductive medicine. In his new role as ... executive board and will have a voice in furthering ... actively supported ASRM since 1984 when he joined while ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... led by Professor Andre Geim, a recipient of the 2010 ... a flow of electrons can magnetise graphene. ... potentially huge breakthrough in the field of spintronics. Spintronics ... spin of the electron, in addition to its fundamental electric ...
... IRVINE, Calif., April 15, 2011 CryoLife, Inc. (NYSE: ... and cardiovascular tissue processing company, today announced it has ... of Cardiogenesis Corporation ("Cardiogenesis") to acquire only 49.9 percent ... On April 14, 2011, Cardiogenesis, CryoLife and CryoLife,s wholly-owned ...
... Therapeutics, a company that manufactures novel blood plasma-based biomaterials ... on a Series A financing it will use to ... early clinical validation for the Company,s first products. ... Capital Partners, a private investment firm that invests in ...
Cached Biology Technology:New spin on graphene 2CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 2CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 3CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 4CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 5CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 6CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 7Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... & Science University researchers have identified some of the ... caused by multiple sclerosis (MS), complications of premature birth, ... clues about why the nervous system fails to repair ... of brain damage could be reversed. The research is ...
... information can be processed unconsciously when the area of ... temporarily shut down, according to research at Rice University ... Oct. 31 in the Proceedings of the National Academy ... has more than one pathway along which visual information ...
... identified some of the key factors that prevent the ... complications of premature birth, and other diseases and conditions. ... system fails to repair itself and suggest ways that ... reversed. The research is published in the August edition ...
Cached Biology News:Molecular Partners Required For Appropriate Neuronal Gene Repression 2Molecular Partners Required For Appropriate Neuronal Gene Repression 3Molecular Partners Required For Appropriate Neuronal Gene Repression 4Out of sight, out of mind? Not necessarily 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 3OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 4
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
... a synthetic peptide whose sequence is from the C-terminal end of the ... extends from amino acids 429 to 448 of RAR*. The sequence ... - V - S - P - S - S - V ... - Q - S - P - L - L - Q ...
... The ELx50 is a fast and versatile ... with our patented Dual-ActionTM 16-channel manifold. This ... the dispense and aspiration manifolds for overfill ... and 384-well formats. The problem of fitting ...
... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
Biology Products: